Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Microbial Pathogenesis
- Vol. 120, 155-160
Abstract
No abstract availableKeywords
Funding Information
- Pasteur Institute of Iran
This publication has 30 references indexed in Scilit:
- Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis VaccinePLOS Pathogens, 2013
- Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteriaNature Reviews Microbiology, 2008
- Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussisClinical and Experimental Immunology, 2006
- Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccinationApplied Microbiology and Biotechnology, 2005
- Mucosal and Cellular Immune Responses Elicited by RecombinantLactococcus lactisStrains Expressing Tetanus Toxin Fragment CInfection and Immunity, 2004
- Intranasal Immunization with RecombinantLactococcus lactisSecreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine ProductionInfection and Immunity, 2003
- Immunoglobulin A-Mediated Protection againstBordetella pertussisInfectionInfection and Immunity, 2001
- Protection againstBordetella pertussisin Mice in the Absence of Detectable Circulating Antibody: Implications for Long‐Term Immunity in ChildrenThe Journal of Infectious Diseases, 2000
- Distinct T‐cell subtypes induced with whole cell and acellular pertussis vaccines in childrenImmunology, 1998
- Mutants of Pertussis Toxin Suitable for Vaccine DevelopmentScience, 1989